Medivir

Medivir is a publicly traded, clinical-stage oncology company with a legacy in antiviral drug discovery, most notably contributing to the hepatitis C therapy simeprevir. The company has successfully pivoted to focus exclusively on cancer, applying its proprietary platforms to develop novel therapies for hard-to-treat tumors. Its strategy centers on advancing its lead asset, fostroxacitabine bralpamide, in liver cancer while expanding its pipeline through targeted discovery and partnerships. Medivir's mission is to deliver innovative treatments where current options are limited or non-existent.

Two proprietary platforms: 1) Structure-based design of selective small-molecule protease inhibitors, and 2) Design of tumor-targeted nucleoside/nucleotide prodrugs that cause lethal DNA damage.

In HCC, fostrox competes with systemic TKIs and immunotherapies but is differentiated by its liver-targeted design. Its protease platform competes on a target-by-target basis, where Medivir's historical selectivity expertise is a key advantage. The company's small size allows for agility in niche oncology targets.